• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»dietary supplements

Why PureHealth Research’s berberine GLP-1 supplement push enters a crowded evidence debate

By Pallavi Madhiraju on May 9, 2026   Pharma & Biotech  

Why PureHealth Research’s berberine GLP-1 supplement push enters a crowded evidence debate

GLP-1 demand is reshaping supplements. PureHealth Research’s berberine launch tests where wellness claims meet evidence and regulation.

OLLY launches Precise Probiotics: Is targeted gut health the next big wellness trend

By Pallavi Madhiraju on April 24, 2026   Pharma & Biotech  

OLLY launches Precise Probiotics: Is targeted gut health the next big wellness trend

Explore how OLLY’s Precise Probiotics could reshape gut health trends and personalized wellness. Find out what this means for consumers today.

Are lymphatic system supplements moving from folklore to functional claims? A look at PureHealth Research

By Pallavi Madhiraju on February 21, 2026   Pharma & Biotech  

Are lymphatic system supplements moving from folklore to functional claims? A look at PureHealth Research

Explore what PureHealth Research’s lymphatic supplement launch reveals about evidence gaps, regulation, and risks in botanical congestion relief.

Anathapindika Health expands retail footprint, testing detox-first nutraceutical demand in specialty stores

By Soujanya Ravi on February 6, 2026   Features & Analysis  

Anathapindika Health expands retail footprint, testing detox-first nutraceutical demand in specialty stores

Discover what Anathapindika Health’s AlchePharma retail expansion signals for detox-focused nutraceuticals and the evolving wellness retail landscape.

Naturmega’s Ruby-O shows bioavailability edge over standard fish oil in peer-reviewed trial

By Pallavi Madhiraju on January 20, 2026   Pharma & Biotech  

Naturmega’s Ruby-O shows bioavailability edge over standard fish oil in peer-reviewed trial

Naturmega’s Ruby-O Balance showed better triglyceride response at a lower dose than fish oil. Find out what this means for the future of omega-3 delivery.

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes